CABALETTA BIO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CABALETTA BIO, INC. (CABA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$22.63 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2024-11-14
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$17.95M, a 246.63% decline year-over-year.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $12.24M.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$62.67M.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$4.15M.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $111.63M.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$40.62M, a 295.33% decline from fiscal 2021.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $20.79M.
- CABALETTA BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$34.77M, a 133.70% decline from fiscal 2019.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$22.63M 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | -$14.63M 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | -$17.95M 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $111.63M 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $33.89M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $46.47M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $12.24M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$40.62M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | -$61.06M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$75.05M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$62.67M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $20.79M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $16.83M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$1.93M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$4.15M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$34.77M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | -$27.52M 10-Q · filed 2021-11-01 | |||
| 2020-06-30 | -$24.11M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$5.20M 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | $103.19M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $38.02M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | $42.24M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $47.22M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $33.02M 10-K · filed 2020-03-30 | |||
| 2018-09-30 | $9.78M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |